Equities research analysts expect Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings per share of $1.97 for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Gilead Sciences’ earnings. The highest EPS estimate is $2.29 and the lowest is $1.72. Gilead Sciences reported earnings of $1.68 per share during the same quarter last year, which indicates a positive year over year growth rate of 17.3%. The business is scheduled to issue its next earnings report on Thursday, April 29th.
On average, analysts expect that Gilead Sciences will report full-year earnings of $7.21 per share for the current financial year, with EPS estimates ranging from $6.90 to $7.59. For the next year, analysts anticipate that the business will report earnings of $7.14 per share, with EPS estimates ranging from $6.63 to $7.55. Zacks’ EPS calculations are an average based on a survey of analysts that cover Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, February 4th. The biopharmaceutical company reported $2.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.15 by $0.04. The company had revenue of $7.42 billion for the quarter, compared to analyst estimates of $7.11 billion. Gilead Sciences had a net margin of 5.48% and a return on equity of 37.77%.
Several research firms have recently weighed in on GILD. Redburn Partners raised Gilead Sciences from a “neutral” rating to a “buy” rating in a report on Tuesday, March 30th. Piper Sandler decreased their price objective on Gilead Sciences from $84.00 to $80.00 and set an “overweight” rating for the company in a report on Tuesday, December 15th. Smith Barney Citigroup decreased their price target on Gilead Sciences from $75.00 to $72.00 in a report on Tuesday, December 22nd. Truist Financial decreased their price target on Gilead Sciences from $67.00 to $625.00 in a report on Friday, December 18th. Finally, Robert W. Baird increased their price objective on Gilead Sciences from $63.00 to $67.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 16th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $96.04.
In other news, EVP Brett A. Pletcher sold 1,486 shares of the company’s stock in a transaction on Thursday, March 11th. The stock was sold at an average price of $63.36, for a total value of $94,152.96. Following the completion of the sale, the executive vice president now owns 29,166 shares in the company, valued at $1,847,957.76. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Brett A. Pletcher sold 1,975 shares of the company’s stock in a transaction on Wednesday, February 10th. The shares were sold at an average price of $67.41, for a total value of $133,134.75. Following the completion of the sale, the executive vice president now owns 28,832 shares of the company’s stock, valued at approximately $1,943,565.12. The disclosure for this sale can be found here. Corporate insiders own 0.13% of the company’s stock.
A number of hedge funds have recently modified their holdings of GILD. Greylin Investment Mangement Inc. boosted its stake in Gilead Sciences by 11.6% during the 4th quarter. Greylin Investment Mangement Inc. now owns 96,969 shares of the biopharmaceutical company’s stock valued at $5,649,000 after purchasing an additional 10,103 shares during the period. Monarch Capital Management Inc. increased its holdings in Gilead Sciences by 2.9% during the 4th quarter. Monarch Capital Management Inc. now owns 67,369 shares of the biopharmaceutical company’s stock valued at $3,925,000 after purchasing an additional 1,888 shares in the last quarter. Kestra Private Wealth Services LLC increased its holdings in Gilead Sciences by 71.2% during the 4th quarter. Kestra Private Wealth Services LLC now owns 38,271 shares of the biopharmaceutical company’s stock valued at $2,168,000 after purchasing an additional 15,917 shares in the last quarter. LS Investment Advisors LLC increased its holdings in Gilead Sciences by 3.1% during the 4th quarter. LS Investment Advisors LLC now owns 61,892 shares of the biopharmaceutical company’s stock valued at $3,606,000 after purchasing an additional 1,881 shares in the last quarter. Finally, Kempen Capital Management N.V. increased its holdings in Gilead Sciences by 22.0% during the 4th quarter. Kempen Capital Management N.V. now owns 345,770 shares of the biopharmaceutical company’s stock valued at $20,144,000 after purchasing an additional 62,378 shares in the last quarter. 76.36% of the stock is currently owned by institutional investors.
Gilead Sciences stock traded down $0.57 during mid-day trading on Wednesday, hitting $64.54. The company had a trading volume of 311,255 shares, compared to its average volume of 8,493,329. The stock has a market cap of $81.26 billion, a price-to-earnings ratio of 67.12, a PEG ratio of 0.67 and a beta of 0.51. Gilead Sciences has a 1 year low of $56.56 and a 1 year high of $85.79. The company has a quick ratio of 3.15, a current ratio of 3.25 and a debt-to-equity ratio of 1.65. The business has a fifty day moving average of $64.22 and a 200 day moving average of $62.47.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 30th. Stockholders of record on Monday, March 15th were issued a $0.71 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.68. The ex-dividend date was Friday, March 12th. This represents a $2.84 annualized dividend and a dividend yield of 4.40%. Gilead Sciences’s dividend payout ratio is 46.25%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
Recommended Story: What impact do institutional investors have on markets?
For more information about research offerings from Zacks Investment Research, visit Zacks.com